Trial Profile
A phase 3 trial investigating TG-4010 in the treatment of non-small cell lung cancer.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 18 Dec 2019
Price :
$35
*
At a glance
- Drugs TG 4010 (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Transgene
- 12 Dec 2019 According to a Transgene media release, status changed from planning to withdrawn prior to enrolment, as company has taken the decision to stop further development of TG4010.
- 10 Feb 2015 New trial record